Iovance To Press Ahead With Melanoma Cell Therapy Filing Despite Doubters
Still Expects To File In 2022
Iovance has seen its share price collapse after releasing data from a second melanoma patient cohort – but is confident its potential first-in-class therapy is approvable.
